Helsinn is a pharmaceutical company with headquarters in Switzerland and subsidiaries in Ireland, United States, China and Monaco.
We are a cancer care company focused on improving and supporting the quality of life of cancer patients by making available cancer therapeutics and cancer supportive care products.
We celebrated our 40th anniversary in 2016. Our founder, Dr. Gabriele Braglia started Helsinn in 1976 with a simple pharmaceutical licensing business in mind. After four decades, the group has grown to being one of the global leaders in its field, has 650 employees and a global network of more than 90 commercial and marketing partners who work with us to offer a large portfolio of cancer-care therapies in almost every country and territories worldwide. Helsinn Group operations have a ‘glocal’ orientation and are managed as centrally as necessary to ensure alignment of critical management aspects, while operating as locally as possible.
This organization has not yet disclosed their sustainability risks on this profile
This organization has not yet disclosed their sustainability opportunities on this profile